Latest From Scrip Team
Pipeline Watch: 12 Approvals And 27 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Oncorus, Orphazyme and More
Recent executive moves in the industry include C-suite changes at Oncorus and Gamida Cell. Meanwhile, new directors were appointed at Orphazyme and Viatris.
Pipeline Watch: 10 Approvals And Six Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Kintor, Nexus and More
Recent executive moves in the industry include C-suite changes at Kintor Pharmaceutical and Antisense Therapeutics. Meanwhile, new directors were appointed at Nexus Pharmaceuticals and BiomX.
Pipeline Watch: 16 Approvals And 16 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Grifols, Voyager and More
Recent executive moves in the industry include C-suite changes at Grifols and Zevra Therapeutics. Meanwhile, new directors were appointed at Voyager Therapeutics and Transgene.